Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum

Human Molecular Genetics

Volumn 12, Issue 21, 2003, Pages 2827-2836

  Régulier, Etienne ^a   Trottier, Yvon ^b   Perrin, Valérie ^a   Aebischer, Patrick ^a   Déglon, Nicole ^a  

^a EPFL   (Switzerland)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; HUNTINGTIN; LENTIVIRUS VECTOR; MOLECULAR MARKER; MUTANT PROTEIN; PHOSPHOPROTEIN DARPP 32; TETRACYCLINE; TRANSACTIVATOR PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC CODE; HUNTINGTON CHOREA; IMMUNOREACTIVITY; IN VIVO STUDY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PROCESSING; RAT; WILD TYPE;

ANIMALS; CELL NUCLEUS; CORPUS STRIATUM; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOXYCYCLINE; FEMALE; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; HUNTINGTON DISEASE; LENTIVIRUS; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; RATS; RATS, WISTAR; TETRACYCLINE;

ANIMALIA; LENTIVIRUS; RNA VIRUSES; RODENTIA;

EID: 0242609127     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/ddg305     Document Type: Article

References (46)

1. Nakamura, K., Jeong, S.Y., Uchihara, T., Anno, M., Nagashima, K., Nagashima, T., Ikeda, S., Tsuji, S. and Kanazawa, I. (2001) SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet., 10, 1441-1448.
2. Zoghbi, H. and Botas, J. (2002) Mouse and fly models of neurodegeneration. Trends Genet., 18, 463-471.
3. Mangiarini, L.F.-S., Sathasivam, K.F.-S., Seller, M.F.-C., Cozens, B.F.-H., Harper, A.F.-H., Hetherington, C.F.-L., Lawton, M.F.-T., Trottier, Y.F.-L., Lehrach, H.F.-D., Davies, S.W.F.-B. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
4. White, J.K., Auerbach, W., Duyao, M.P., Vonsattel, J.P., Gusella, J.F., Joyner, A.L. and MacDonald, M.E. (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet., 17, 404-410.
5. Reddy, P.H., Williams, M., Charles, V., Garrett, L., Pike-Buchanan, L., Whetsell, W.O. Jr, Miller, G. and Tagle, D.A. (1998) Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet., 20, 198-202.
6. Hodgson, J.G., Agopyan, N., Gutekunst, C.A., Leavitt, B.R., LePiane, F., Singaraja, R., Smith, D.J., Bissada, N., McCutcheon, K., Nasir, J. et al. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal. neurodegeneration. Neuron, 23, 181-192.
7. Schilling, G., Becher, M.W., Sharp, A.H., Jinnah, H.A., Duan, K., Kotzuk, J.A., Slunt, H.H., Ratovitski, T., Cooper, J.K., Jenkins, N.A. et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet., 8, 397-407.
8. Shelbourne, P.F., Killeen, N., Hevner, R.F., Johnston, H.M., Tecott, L., Lewandoski, M., Ennis, M., Ramirez, L., Li, Z., Iannicola, C. et al. (1999) A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet., 8, 763-774.
9. Wheeler, V.C., Auerbach, W., White, J.K., Srinidhi, J., Auerbach, A., Ryan, A., Duyao, M.P., Vrbanac, V., Weaver, M., Gusella, J.F. et al. (1999) Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet., 8, 115-122.
10. Yamamoto, A., Lucas, J.J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 101, 57-66.
11. Lin, C.H., Tallaksen-Greene, S., Chien, W.M., Cearley, J.A., Jackson, W.S., Crouse, A.B., Ren, S., Li, X.J., Albin, R.L. and Detloff, P.J. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet., 10, 137-144.
12. Reddy, P.H., Williams, M. and Tagle, D.A. (1999) Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci., 22, 248-255.
13. Hurlbert, M.S., Zhou, W., Wasmeier, C., Kaddis, F.G., Hutton, J.C. and Freed, C.R. (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes, 48, 649-651.
14. Déglon, N., Régulier, E., Palfi, S., Bloch, J., Aebischer, P. and Hantraye, P. (2003) Intraneural Aggregates, Striatal Dysfunction and Behavioral Deficits Following Lentiviral Overexpression of Mutated Huntingtin in Rats and Non-human Primates. ASGT, Washington, DC.
15. de Almeida, L.P., Ross, C.A., Zala, D., Aebischer, P. and Déglon, N. (2002) Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci., 22, 3473-3483.
16. Yoo, S.Y., Pennesi, M.E., Weeber, E.J., Xu, B., Atkinson, R., Chen, S., Armstrong, D.L., Wu, S.M., Sweatt, J.D. and Zoghbi, H.Y. (2003) SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron, 37, 383-401.
17. Régulier, E., Pereira de Almeida, L., Sommer, B., Aebischer, P. and Déglon, N. (2002) Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum. Gene Ther, 13, 1981-1990.
18. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M. and Trono, D. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272, 263-267.
19. Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L. and Trono, D. (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol., 15, 871-875,
20. Knott, A., Garke, K., Urlinger, S., Guthmann, J., Muller, Y., Thellmann, M. and Hillen, W. (2002) Tetracycline-dependent gene regulation: combinations of transregulators yield a variety of expression windows. Biotechniques, 32, 796, 798, 800.
21. Vigna, E., Cavalieri, S., Ailles, L., Geuna, M., Loew, R., Bujard, H. and Naldini, L. (2002) Robust and efficient regulation of trunsgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol. Ther., 5, 252-261.
22. DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990-1993.
23. Lunkes, A. and Mandel, J.L. (1998) A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet., 7, 1355-1361.
24. Saudou, F., Finkbeiner, S., Devys, D. and Greenberg, M.E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 95, 55-66.
25. Li, H., Li, S.H., Johnston, H., Shelbourne, P.F. and Li, X.J. (2000) Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet., 25, 385-389.
26. Lunkes, A., Lindenberg, K.S., Ben-Haiem, L., Weber, C., Devys, D., Landwehrmeyer, G.B., Mandel, J.L. and Trottier, Y. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell, 10, 259-269.
27. Sun, B., Fan, W., Balciunas, A., Cooper, J.K., Bitan, G., Steavenson, S., Denis, P.E., Young, Y., Adler, B., Daugherty, L. et al. (2002) Polyglutamine repeat length-dependent proteolysis of huntingtin. Neurobiol. Dis., 11, 111-122.
28. Chen, M., Ona, V.O., Li, M., Ferrante, R.J., Fink, K.B., Zhu, S., Bian, J., Guo, L., Farrell, L.A., Hersch, S.M. et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med., 6, 797-801.
29. Fernandez-Funez, P., Nino-Rosales, M.L., de Gouyon, B., She, W.C., Luchak, J.M., Martinez, P., Turiegano, E., Benito, J., Capovilla, M., Skinner, P.J. et al. (2000) Identification of genes that modify ataxin-1-induced neurodegeneration. Nature, 408, 101-106.
30. Gusella, J.F. and MacDonald, M.E. (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative digease. Nat. Rev. Neurosci., 1, 109-115.
31. Wellington, C.L. and Hayden, M.R. (2000) Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clin. Genet., 57, 1-10.
32. Kim, Y.J., Yi, Y., Sapp, E., Wang, Y., Cuiffo, B., Kegel, K.B., Qin, Z.H., Aronin, N. and DiFiglia, M. (2001) Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl Acad. Sci. USA, 98, 12784-12789.
33. Gafni, J. and Ellerby, L.M. (2002) Calpain activation in Huntington's disease. J. Neurosci., 22, 4842-4849.
34. Toneff, T., Mende-Mueller, L., Wu, Y., Hwang, S.R., Bundey, R., Thompson, L.M., Chesselet, M.F. and Hook, V. (2002) Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain. J. Neurochem., 82, 84-92.
35. Goffredo, D., Rigamonti, D., Tartari, M., De Micheli, A., Verderio, C., Matteoli, M., Zuccato, C. and Cattaneo, E. (2002) Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. J. Biol. Chem., 277, 39594-39598.
36. Gossen, M. and Bujard, H. (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA, 89, 5547-5551.
37. Déglon, N., Tseng, J.L., Bensadoun, J.C., Zurn, A.D., Arsenijevic, Y., Pereira de Almeida, L., Zufferey, R., Trono, D. and Aebischer, P. (2000) Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther., 11, 179-190.
38. Yu, Z.X., Li, S.H., Evans, J., Pillarisetti, A., Li, H. and Li, X.J. (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci., 23, 2193-2202.
39. Chai, Y., Wu, L., Griffin, J.D. and Paulson, H.L. (2001) The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J. Biol. Chem., 276, 44889-44897.
40. Bates, G. (2003) Huntingtin aggregation and toxicity in Huntington's disease. Lancet, 361, 1642-1644.
41. Xia, H., Mao, Q., Paulson, H.L. and Davidson, B.L. (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol., 20, 1006-1010.
42. Abbas-Terki, T., Blanco-Bose, W., Deglon, N., Pralong, W. and Aebischer, P. (2002) Lentiviral-mediated RNA interference. Hum. Gene Ther., 13, 2197-2201.
43. Miller, V.M., Xia, H., Marrs, G.L., Gouvion, C.M., Lee, G., Davidson, B.L. and Paulson, H.L. (2003) Allele-specific silencing of dominant disease genes. Proc. Natl Acad. Sci. USA, 100, 7195-7200.
44. Hackam, A.S., Singaraja, R., Wellington, C.L., Metzler, M., McCutcheon, K., Zhang, T., Kalchman, M. and Hayden, M.R. (1998) The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol., 141, 1097-1105.
45. de Almeida, L.P., Zala, D., Aebischer, P. and Déglon, N. (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol. Dis., 8, 433-446.
46. Bensadoun, J., Pereira de Almeida, L., Dreano, M., Aebischer, P. and Déglon, N. (2001) Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. Eur. J. Neurosci., 14, 1-11.